Abstracts tagged "patient outcomes and spondylarthropathy"

Abstract Number: 2733 • 2016 ACR/ARHP Annual Meeting
Fatigue, Pain and Patient Global Assessment Fluctuate Substantially in Spondyloarthropathy Patients with Stable Disease According to Basdai
Eva Marie Egsmose¹ and Ole Rintek Madsen², ¹Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte Glostrup Rigshospitalet, Hellerup, Denmark, ²Center for Rheumatology and Spine Diseases & The DANBIO Registry, Copenhagen University Hospital Gentofte Glostrup Rigshospitalet, Hellerup, Denmark
Background/Purpose: The use of patient-reported outcome measures has become routine in clinical practice and in clinical trials. In order to use any outcome measure in…
Abstract Number: 681 • 2015 ACR/ARHP Annual Meeting
Impact of Disease Duration on Patient Reported and Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Anti-TNF: An Analysis from a Prospective, Observational Registry
Michael Starr¹, Michel Zummer², Denis Choquette³, Boulos Haraoui⁴, Dalton Sholter⁵, Regan Arendse⁶, Isabelle Fortin⁷, Louis Bessette⁸, Proton Rahman⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Allen J Lehman¹², Karina Maslova¹², Brendan Osborne¹³, Francois Nantel^14,15 and Cathy Tkaczyk¹³, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁹Medicine, Memorial University, St John's, NF, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁴Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹⁵19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have shown that treatment outcomes are affected by disease-related aspects (e.g., disease severity and chronicity, treatment type and intensity) and patient-related factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].